Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4329090 in Participants With Obesity or Overweight
NCT07808073Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY4329090 in obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events at Week 28. Started Sep 2026; status: recruiting.
02
Drugs
LY4329090
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07808073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808073.